Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers globally with a
mortality rate exceeding 95% and very limited therapeutic options. A hallmark of PDAC is its …

Cancer cells have altered metabolism and ongoing efforts in developing therapies that
target cancer metabolism are showing promise (DeBerardinis and Chandel 2016). However …

BACKGROUND Pancreatic cancer is a malignant tumor with a high mortality rate and is
expected to become the second-leading cause of cancer mortality in the United States by …

Metabolic reprogramming is one of the emerging hallmarks of cancers. As a highly
malignant tumor, pancreatic ductal adenocarcinoma (PDA) is not only a metabolic disease …

Pancreatic cancer is an aggressive and lethal disease with an overall 5-year survival rate of
only 5%. Studies have demonstrated the ability of 18 F-fludrodeoxyglucose (18 F-FDG) …

A major obstacle for the effective treatment of pancreatic ductal adenocarcinoma (PDAC) is
its molecular heterogeneity, reflected by the diverse clinical outcomes and responses to …

Pancreatic ductal adenocarcinoma (PDAC) is a major research focus because of its poor
therapy response and dismal prognosis. PDAC cells adapt their metabolism to the …

Background Patients-derived xenograft (PDX) model have been widely used for tumor
biological and pathological studies. However, the metabolic similarity of PDX tumor to the …

Introduction Pancreatic ductal adenocarcinoma (PDAC) is the fifth most common cause of
cancer-related death in Europe with a 5-year survival rate of< 5%. Chronic pancreatitis (CP) …

Background Evolutionary cancer has a supply mechanism to satisfy higher energy demands
even in poor-nutrient conditions. Metabolic reprogramming is essential to supply sufficient …